A phase I trial was initiated to assess the safety and optimal dose of intraventricularly administered autologous HER2‐targeted chimeric antigen receptor (HER2‐CAR) T cells in patients with brain and/or leptomeningeal metastases from HER2 positive cancers (NCT03696030). Here, ERBB2 is linked to cancer.